Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 34Terminated 11Unknown 9Active not recruiting 5Recruiting 4Withdrawn 3Not yet recruiting 1Available 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 12Lymphoid 8Myeloid 4Plasma cell 3CNS 3Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

venetoclax 33fludarabine 32Cyclophosphamide 31Azacitidine 29Specimen Handling 27Biopsy 20Cytarabine 19fludarabine phosphate 15Whole-Body Irradiation 15Stem Cell Transplantation 15Decitabine 15ruxolitinib 14Tacrolimus 14Melphalan 14Busulfan 14Mycophenolic Acid 13Injections 11asciminib 10decitabine and cedazuridine drug combination 9Thiotepa 8Methotrexate 8Hematopoietic Stem Cell Transplantation 8X-Rays 7Granulocyte Colony-Stimulating Factor 7Magnetic Resonance Spectroscopy 6Idarubicin 6Filgrastim 6Cyclosporine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6tagraxofusp 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Dasatinib × Myeloid × Clear all
NCT04877522 2026-05-11

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Dana-Farber Cancer Institute

Phase 1 Recruiting
40 enrolled
LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Medical College of Wisconsin

Phase 2 Recruiting
51 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04835584 2022-03-21

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Kartos Therapeutics, Inc.

Phase 1/2 Recruiting
109 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡